Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

  • STATUS
    Recruiting
  • End date
    Apr 19, 2024
  • participants needed
    415
  • sponsor
    Boston Scientific Corporation
Updated on 19 September 2021
atrial fibrillation
fibrillation
catheter ablation
paroxysmal atrial fibrillation
atrial ablation

Summary

To obtain data for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according to current international and local guidelines.

Primary objective: To assess acute and long-term outcomes for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergoing first ablation procedure for PAF with no prior left atrial ablation (RF, Cryo, Surgical).

Description

STUDY OBJECTIVE(S) -- To obtain data for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according to current international and local guidelines.

PRIMARY OBJECTIVE -- To assess acute and long-term outcomes for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergoing first ablation procedure for PAF with no prior left atrial ablation (RF, Cryo, Surgical).

INDICATION(S) FOR USE -- Study devices will be used per approved Indications for Use for each geography.

DEVICES / SYSTEM USED IN THE STUDY -- The study will include the following Boston Scientific Open-Irrigated Catheters in geographies where commercially approved for PAF ablation:

  • Blazer Open-Irrigated Ablation Catheter
  • IntellaNav Open-Irrigated Ablation Catheter
  • IntellaNav MiFi Open-Irrigated Ablation Catheter
  • IntellaTip MiFi Open-Irrigated Ablation Catheter
  • Rhythmia Mapping System Gen 1or Rhythmia HDx, equipped with Software 1.4 or any successive commercially approved versions.
  • IntellaMap Orion Catheter

CONTROL DEVICE -- There are no control devices in this study

STUDY DESIGN -- Prospective, non-randomized, multicenter (global), post approval clinical study (PAS). All subjects fitting the enrollment criteria, signing the consent and undergoing the index procedure with the study devices will be followed up for three years to complete the PAS design mandated from the FDA to collect post-market data for Boston Scientific Open-Irrigated Catheters and will be followed for three years.

PLANNED NUMBER OF SUBJECTS -- The study will enroll 415 subjects.

PLANNED NUMBER OF SITES / COUNTRIES -- The study is global (US, EU, Asia-Pacific) with 25-50 centers. A minimum of 50% of the sites will be selected from the US. No study site will be allowed to contribute more than 41 subjects (10% of the 415 enrollments requirement).

FOLLOW-UP SCHEDULE -- Study Follow-ups are at: pre-discharge, 1 month (phone check), 3 months (blanking period), 6 months (phone check), 12 months, 24 months and 36 months.

STUDY DURATION -- Study is expected to be completed in approximately five years (12-24 month enrollment period with three year follow-up).

PARTICIPANT DURATION -- The study duration for each subject is expected to be approximately three years.

Details
Condition Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Atrial Fibrillation (Pediatric), Dysrhythmia, paroxysmal af
Treatment Boston Scientific Open Irrigated Ablation Catheters
Clinical Study IdentifierNCT03729830
SponsorBoston Scientific Corporation
Last Modified on19 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

History of recurrent symptomatic Paroxysmal Atrial Fibrillation, defined as AFib that terminates spontaneously or with intervention within seven days of onset. Minimum documentation includes a physician's note indicating recurrent self-terminating Atrial Fibrillation AND one electrocardiographically documented AF episode within 6 months prior to enrollment
Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation with the Rhythmia Mapping system according to current international and local guidelines
Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation with a Boston Scientific Open-Irrigated Ablation Catheter according to current international and local guidelines
Subjects who are willing and capable of providing informed consent
Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center
Subjects whose age is 20 years or above, or who are of legal age to give informed consent specific to state and national law

Exclusion Criteria

Subjects enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific
Subjects unable or unwilling to complete follow-up visits and examination for the duration of the study
Subjects who have undergone any previous left atrial cardiac ablation (RF, Cryo, surgical)
Subjects who have undergone any cardiac ablation within 30 days prior to enrollment
Unrecovered/unresolved Adverse Events from any previous invasive procedure
Life expectancy <= three years per physician opinion
Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion)
Known cardiac thrombus within 60 days prior to enrollment
History of CVA, TIA or PE within 90 days prior to enrollment
Implanted pacemaker, ICD, or CRT leads within 90 days prior to enrollment
Implanted Left atrial appendage closure device prior to the index procedure
Prosthetic mitral or tricuspid heart valves (subjects with successful mitral valve repair allowed- annular ring constitutes repair)
Left atrial diameter greater than 5.5cm
Documented or suspected stenosis of any pulmonary veins
Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
Contraindication for anticoagulation
Clinically significant mitral valve regurgitation or stenosis per investigator discretion
Any cardiac surgery 90 days from consent date
Any electrocardiographically documented episode of Persistent AFib, defined as AFib lasting longer than 7 days from onset
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note